Lifecore Biomedical Advances Strategic Partnership with Indomo for DT-001 Acne Therapy

Lifecore Biomedical, a leading injectable contract development and manufacturing organization, has established a new development agreement with Indomo, a clinical-stage biotech company focused on dermatological therapeutics. Under this collaboration, Lifecore will deliver comprehensive CDMO services to support the continued progression of DT-001, a corticosteroid-based therapeutic candidate targeting inflammatory skin lesions.

Strategic Collaboration for Acne Therapy Development

This partnership represents the second agreement between the two organizations, building on their prior collaboration on formulation and process optimization. The expanded engagement underscores the growing strategic importance of DT-001 in Lifecore’s therapeutic portfolio and Indomo’s commitment to advancing its innovative treatment platform for acne management.

ClearPen Technology and DT-001 Mechanism

DT-001 is specifically formulated for use with Indomo’s investigational ClearPen device, a proprietary intradermal self-injection system equipped with microneedle technology. The system combines this advanced delivery mechanism with triamcinolone acetonide, a potent corticosteroid formulation designed to ensure precise, consistent dosing for patient self-administration at home. This approach represents a significant innovation in inflammatory acne treatment, enabling patients to manage their condition independently without recurring clinical visits.

Addressing a Major Unmet Clinical Need

Acne remains the most prevalent skin disorder in the United States, impacting approximately 50 million individuals annually. However, the current treatment landscape shows a significant therapeutic gap: only around one million patients regularly access corticosteroid injection therapy for inflammatory lesions. This disparity highlights a substantial market opportunity for more accessible, user-friendly treatment solutions.

Path to Phase 2 Clinical Advancement

Under the terms of this new agreement, Lifecore will be responsible for manufacturing and supplying both engineering and clinical batches of DT-001. These batches will support Indomo’s planned investigational studies, positioning the program for anticipated progression into Phase 2 clinical trials in 2026. This timeline reflects accelerating momentum in the development cycle and increases the likelihood of meaningful clinical validation in the near term.